The Case for Pediatric-Inspired Regimens in AYA ALL: Real-World Evidence and Barriers to Adoption

Dr. Lewis Silverman introduces the program on pediatric-inspired asparaginase-based regimens in adolescent and young adult (AYA) ALL, joined by Dr. Emily Curran. The discussion focuses on the 2026 real-world analysis by Freyer and colleagues, which demonstrated significantly higher overall survival in AYAs with ALL treated with guideline-concordant pediatric-inspired regimens compared to adult-inspired regimens. Dr. Curran notes that no randomized trial comparing pediatric-inspired versus adult regimens in the AYA population has been completed to date; the accumulating retrospective and prospective data nonetheless strongly favor pediatric-inspired regimens over historical adult controls.

Barriers to universal adoption are discussed. First, the absence of head-to-head randomized data allows community providers to argue that adult regimens are comparable, particularly when select adult regimens incorporate asparaginase or other pediatric-based elements. Second, pediatric-inspired regimens are genuinely complex and unfamiliar to adult oncologists trained primarily on cyclophosphamide-based and other conventional adult ALL backbones. Third, asparaginase specifically generates apprehension: it requires specialized knowledge of its adverse event profile, and a single difficult clinical experience can create lasting hesitation. Dr. Curran suggests that community providers who are uncertain about asparaginase use should call pediatric oncology colleagues for guidance, emphasizing that institutional pediatric teams carry extensive asparaginase experience that can be readily shared across practice settings.